RT Journal Article
SR Electronic
T1 Update on pharmacology of antiplatelets, anticoagulants, and thrombolytics
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP S68
OP S76
DO 10.1212/WNL.0b013e3182695871
VO 79
IS 13 Supplement 1
A1 Cheng-Ching, Esteban
A1 Samaniego, Edgar A.
A1 Naravetla, Bharath Reddy
A1 Zaidat, Osama O.
A1 Hussain, Muhammad Shazam
YR 2012
UL http://n.neurology.org/content/79/13_Supplement_1/S68.abstract
AB Understanding of the pharmacology of thrombolytics, anticoagulants, and antiplatelets is critical to performing safe and effective endovascular therapy for acute ischemic therapy. This is a basic review of the clinical pharmacologic data on the anticoagulants, antiplatelets, and fibrinolytic agents most commonly used in the treatment of stroke and in the neurointerventional suite. CYP=cytochrome P450; FDA=US Food and Drug Administration; HIT=heparin-induced thrombocytopenia; LMWH=low-molecular-weight heparin; Pro-UK=prourokinase; rtPA=recombinant tissue plasminogen activator; tPA=tissue plasminogen activator; UFH=unfractionated heparin; VTE=venous thromboembolism